Quantum-Si Inc (QSI) Stock Analysis and Metrics

Quantum-Si

NASDAQ: QSI

$0.77 ▼ -0.02 (-2.54%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap171.01 Mn

P/E-1.65

P/S92.34

Div. Yield0.00

Add ratio to table…

About

Quantum-Si Incorporated is a life sciences company focused on proteomics research with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome. The company has developed a proprietary universal single-molecule detection platform that is applied to proteomics to enable next generation protein sequencing to sequence proteins in a massively parallel fashion. This platform includes the Platinum NGPS instrument, Platinum Analysis Software and consumable kits for use with the Platinum line of instruments. Quantum-Si began a controlled launch of the Platinum instrument in December 2022, started a controlled commercial launch in January 2023 and moved to a full commercial launch in the second quarter of 2024. In January 2025 the company announced the launch of the Platinum Pro benchtop sequencer with first shipments occurring in March 2025. The company continues to develop its next generation platform Proteus which is anticipated to launch by the end of 2026.

Quantum-Si generates revenue primarily through the sale of its instruments consumables and software. The company sells the Platinum and Platinum Pro sequencers which are priced at approximately eighty five thousand dollars and one hundred twenty thousand dollars respectively. Recurring revenue is derived from the sale of consumable kits that are required to run samples on the instruments including Library Preparation Kits Barcoding Kits and Sequencing Kits. Additionally the company offers the Platinum Analysis Software which provides automated data analysis and visualization workflows for users of the sequencing platforms. Revenue is also supported through service and support arrangements that accompany instrument sales and through collaborations with distribution partners such as Avantor in North America.

Quantum-Si occupies a niche within the broader life sciences tools market where it competes with established providers of proteomics technologies such as Agilent Technologies Bio-Rad Laboratories Danaher Luminex Merck KGaA and Thermo Fisher Scientific. The company differentiates itself through its single molecule kinetic detection technology which delivers amino acid level resolution without reliance on ensemble measurements. Its instruments are priced significantly lower than traditional mass spectrometry systems which often cost one million dollars or more per unit. The integrated Platinum Analysis Software simplifies data interpretation and reduces the need for specialized bioinformatics staff. Quantum-Si holds a robust intellectual property portfolio with four hundred two issued patents and three hundred forty eight pending applications as of December 31 2025 which provides a barrier to entry for potential competitors. The company strategy emphasizes accessibility by offering a low capital cost platform that includes automated workflows enabling adoption in both core laboratories and smaller research settings.

Quantum-Si serves a diverse customer base that includes academic research institutions biopharmaceutical companies contract development and manufacturing organizations government agencies and industrial laboratories. The company’s early access program engaged leading academic centers and key industry partners to validate its technology across various applications. While specific customer names are not disclosed in the filing the company indicates that its products are used for biomarker discovery disease detection pathway analysis immune response studies vaccine development and quality assurance and quality control workflows. The platform is intended for research use only although the data generated may support future diagnostic and therapeutic development efforts.

Investment Thesis

▲ Bull case

Quantum-Si is on track to deliver a fully integrated Proteus platform with 18 amino acid detection by commercial launch in 2026, with the capability to demonstrate all 20 amino acids during the year, representing a significant de-risking of its core technology platform. The successful sequencing milestone achieving 17 amino acid detection—up from 15 in December 2025—shows rapid technical progress, and management's confidence in hitting 18 by launch and all 20 by year-end is backed by improvements in detection frequency across all amino acids and better signal-to-noise ratios. This advancement directly enables broader proteome coverage and longer average read lengths, which early customer feedback confirms doubles the data output versus Platinum, making the platform substantially more powerful for complex applications like de novo sequencing and variant detection. The company is not relying on speculative innovation but is now in the execution phase focused on reliability, precision, and throughput—standard systems engineering work that reduces technical risk and increases confidence in timely commercialization. This positions Proteus to capture demand not only from existing Platinum users seeking upgrades but also from entirely new customer segments in biopharma and clinical research that were previously inaccessible due to Platinum's limitations in detecting post-translational modifications (PTMs) at scale.
The Proteus roadshow strategy is generating stronger-than-expected institutional engagement, with events drawing higher attendance than registrations and participants dedicating approximately two hours per session—far exceeding typical sales call durations—indicating deep scientific interest and qualified lead generation. Early roadshows have already attracted researchers focused on PTM analysis, a high-value application area where current solutions like mass spectrometry require expensive equipment (often over $1 million), complex sample preparation, and specialized bioinformatics expertise. By positioning Proteus at $425 thousand as a more affordable, automated alternative with universal kinetic signature-based PTM detection, Quantum-Si is tapping into a significant unmet need in translational research, clinical proteomics, and biopharma development. Management’s observation of no pricing pushback to date, combined with customer feedback citing the price as "very reasonable for its capabilities," suggests the value proposition is resonating and could drive faster-than-anticipated adoption upon launch, especially as early access units begin placements in academic and commercial settings this summer to generate real-world performance data and publications.
Quantum-Si’s financial positioning provides a durable runway to support Proteus launch and early commercialization, with $190.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, sufficient to fund operations into the Q2 FY28—approximately 18 months post-launch. This liquidity buffer reduces near-term financing risk and allows the company to prioritize long-term platform adoption over short-term revenue maximization, as evidenced by deliberate strategies like embedding upgrade credits in Platinum Pro units and accepting delayed customer purchasing decisions ahead of Proteus availability. Furthermore, insider confidence is reinforced by two board members collectively purchasing 600,000 shares in open market transactions during the quarter with no open-market sales by management outside of plan-mandated transactions, signaling alignment between leadership and shareholders. Post-launch, the company anticipates operating expense leverage as development spend rolls off and external partners enable a ratcheting down of R&D costs, creating flexibility to reinvest savings into high-return commercialization initiatives as Proteus gains traction—potentially accelerating the path to profitability without sacrificing growth.

Quantum-Si is on track to deliver a fully integrated Proteus platform with 18 amino acid detection by commercial launch in 2026, with the capability to demonstrate all 20 amino acids during the year, representing a significant de-risking of its core technology platform. The successful sequencing milestone achieving 17 amino acid detection—up from 15 in December 2025—shows rapid technical progress, and management's confidence in hitting 18 by launch and all 20 by year-end is backed by improvements in detection frequency across all amino acids and better signal-to-noise ratios. This advancement directly enables broader proteome coverage and longer average read lengths, which early customer feedback confirms doubles the data output versus Platinum, making the platform substantially more powerful for complex applications like de novo sequencing and variant detection. The company is not relying on speculative innovation but is now in the execution phase focused on reliability, precision, and throughput—standard systems engineering work that reduces technical risk and increases confidence in timely commercialization. This positions Proteus to capture demand not only from existing Platinum users seeking upgrades but also from entirely new customer segments in biopharma and clinical research that were previously inaccessible due to Platinum's limitations in detecting post-translational modifications (PTMs) at scale.
The Proteus roadshow strategy is generating stronger-than-expected institutional engagement, with events drawing higher attendance than registrations and participants dedicating approximately two hours per session—far exceeding typical sales call durations—indicating deep scientific interest and qualified lead generation. Early roadshows have already attracted researchers focused on PTM analysis, a high-value application area where current solutions like mass spectrometry require expensive equipment (often over $1 million), complex sample preparation, and specialized bioinformatics expertise. By positioning Proteus at $425 thousand as a more affordable, automated alternative with universal kinetic signature-based PTM detection, Quantum-Si is tapping into a significant unmet need in translational research, clinical proteomics, and biopharma development. Management’s observation of no pricing pushback to date, combined with customer feedback citing the price as "very reasonable for its capabilities," suggests the value proposition is resonating and could drive faster-than-anticipated adoption upon launch, especially as early access units begin placements in academic and commercial settings this summer to generate real-world performance data and publications.
Quantum-Si’s financial positioning provides a durable runway to support Proteus launch and early commercialization, with $190.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, sufficient to fund operations into the Q2 FY28—approximately 18 months post-launch. This liquidity buffer reduces near-term financing risk and allows the company to prioritize long-term platform adoption over short-term revenue maximization, as evidenced by deliberate strategies like embedding upgrade credits in Platinum Pro units and accepting delayed customer purchasing decisions ahead of Proteus availability. Furthermore, insider confidence is reinforced by two board members collectively purchasing 600,000 shares in open market transactions during the quarter with no open-market sales by management outside of plan-mandated transactions, signaling alignment between leadership and shareholders. Post-launch, the company anticipates operating expense leverage as development spend rolls off and external partners enable a ratcheting down of R&D costs, creating flexibility to reinvest savings into high-return commercialization initiatives as Proteus gains traction—potentially accelerating the path to profitability without sacrificing growth.

▼ Bear case

Quantum-Si’s revenue trajectory remains critically dependent on the successful and timely commercial launch of Proteus by the end of 2026, with first-quarter 2026 revenue of only $258 thousand underscoring the near-total collapse of legacy Platinum demand as customers delay purchases in anticipation of the new platform. The company’s full-year 2026 revenue guidance of approximately $1 million is not reflective of organic demand but rather a function of minimal Platinum consumable revenue and very modest new capital sales, indicating that the business is currently generating negligible recurring revenue streams. Should Proteus face any delays in technical validation, manufacturing scale-up, or regulatory readiness, the company risks a significant air pocket in revenue with no near-term offset, especially given that Platinum is positioned as a transitional product with no long-term growth potential. The reliance on a single product transition creates binary outcomes: success drives re-rating, but any stumble in launch execution could precipitate a severe loss of investor confidence and necessitate dilutive financing despite the current cash runway.
While management emphasizes strong interest in Proteus roadshows and early customer feedback on increased amino acid detection and read length, there is a lack of concrete leading indicators of commercial conversion, such as pre-orders, binding letters of intent, or quantified early access commitments beyond a vague "handful" of units targeted for academic and biopharma settings by summer and fall. The absence of specific metrics on early access site numbers or funnel progression makes it difficult to assess whether the observed engagement translates into actual purchasing intent, particularly at the $425 thousand price point. Although no pricing pushback has been reported to date, this feedback is premature given that most roadshow attendees are still in the educational phase and have not yet undergone formal budgeting or capital approval processes; true price sensitivity may only emerge when customers are required to allocate real budget dollars, potentially revealing resistance if competing technologies or internal budget constraints limit adoption. Furthermore, the company’s suggestion that Proteus will open up entirely new customer segments in biopharma and clinical research remains unproven, as these segments often have entrenched workflows, validation requirements, and procurement cycles that could slow adoption despite technological advantages.
Quantum-Si’s path to profitability hinges on post-launch operating expense leverage through reduced R&D spend via external partners, but this assumption carries execution risk if the company fails to successfully transition development activities to manufacturing partners or if post-launch support demands unexpected R&D investment. The adjusted operating expense guidance of $98 million or less for 2026 already reflects disciplined cost control, yet the company reported a net loss of $21.7 million in Q1 2026, and achieving profitability will require not just launch success but a rapid ramp in Proteus placements and high-margin consumable revenue to offset fixed costs. There is no discussion in the transcript of expected gross margins for Proteus versus Platinum, nor any detail on consumable pricing, yield, or recurring revenue potential—critical unknowns that determine whether the platform can sustain a profitable business model. Without visibility into the consumable-driven economics of Proteus, the market cannot assess whether the company will achieve the recurring revenue profile necessary to justify its current valuation, leaving profitability as a hopeful outcome rather than a near-term expectation.

Quantum-Si’s revenue trajectory remains critically dependent on the successful and timely commercial launch of Proteus by the end of 2026, with first-quarter 2026 revenue of only $258 thousand underscoring the near-total collapse of legacy Platinum demand as customers delay purchases in anticipation of the new platform. The company’s full-year 2026 revenue guidance of approximately $1 million is not reflective of organic demand but rather a function of minimal Platinum consumable revenue and very modest new capital sales, indicating that the business is currently generating negligible recurring revenue streams. Should Proteus face any delays in technical validation, manufacturing scale-up, or regulatory readiness, the company risks a significant air pocket in revenue with no near-term offset, especially given that Platinum is positioned as a transitional product with no long-term growth potential. The reliance on a single product transition creates binary outcomes: success drives re-rating, but any stumble in launch execution could precipitate a severe loss of investor confidence and necessitate dilutive financing despite the current cash runway.
While management emphasizes strong interest in Proteus roadshows and early customer feedback on increased amino acid detection and read length, there is a lack of concrete leading indicators of commercial conversion, such as pre-orders, binding letters of intent, or quantified early access commitments beyond a vague "handful" of units targeted for academic and biopharma settings by summer and fall. The absence of specific metrics on early access site numbers or funnel progression makes it difficult to assess whether the observed engagement translates into actual purchasing intent, particularly at the $425 thousand price point. Although no pricing pushback has been reported to date, this feedback is premature given that most roadshow attendees are still in the educational phase and have not yet undergone formal budgeting or capital approval processes; true price sensitivity may only emerge when customers are required to allocate real budget dollars, potentially revealing resistance if competing technologies or internal budget constraints limit adoption. Furthermore, the company’s suggestion that Proteus will open up entirely new customer segments in biopharma and clinical research remains unproven, as these segments often have entrenched workflows, validation requirements, and procurement cycles that could slow adoption despite technological advantages.
Quantum-Si’s path to profitability hinges on post-launch operating expense leverage through reduced R&D spend via external partners, but this assumption carries execution risk if the company fails to successfully transition development activities to manufacturing partners or if post-launch support demands unexpected R&D investment. The adjusted operating expense guidance of $98 million or less for 2026 already reflects disciplined cost control, yet the company reported a net loss of $21.7 million in Q1 2026, and achieving profitability will require not just launch success but a rapid ramp in Proteus placements and high-margin consumable revenue to offset fixed costs. There is no discussion in the transcript of expected gross margins for Proteus versus Platinum, nor any detail on consumable pricing, yield, or recurring revenue potential—critical unknowns that determine whether the platform can sustain a profitable business model. Without visibility into the consumable-driven economics of Proteus, the market cannot assess whether the company will achieve the recurring revenue profile necessary to justify its current valuation, leaving profitability as a hopeful outcome rather than a near-term expectation.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password